SESSIONS WILL BE DIVIDED INTO 3 TRACKS PRIOR TO THE EVENT. DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
THE DAY WILL START AT 09:00 AND CONCLUDE WITH A NETWORKING RECEPTION PRIOR TO THE EVENT FINISHING AT 17.00.
Do the right thing
Plenary panel: Brexit – cliff edge or catapult?
Leadership lessons learnt – navigating through dramatic change
How do you like your therapy area? Rare.
It’s a no brainer
Scouting for tech
Back to the future
The logic in biologics
Reflecting on the pharma trends of 2010 – 2020, and predicting what is to come in the next decade.
Accessing and stratifying patient groups for clinical trials and maximising clinical data.
What strategies are we putting in place to ensure new drugs hit the 5Rs?
With the end of the transition period in sight, will Brexit bring a fanfare or a frenzy to Pharma?
KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting
PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics
SIMON HURST | Chief Executive Officer | Sygnature Discovery
EMMA SCEATS | Chief Executive | Isogenica
MICHELE LESUEUR | Hematology Oncology Business Unit Director | Celgene
The growing focus on rare diseases and what this means for clinical trials.
Respiratory diseases remain a key target for pharma companies. Are we maximising our assets and this as a drug delivery route?
Are biologics and antibody-drug conjugates deliverying on their promise?
With large pharma moving away from neuroscience, has it been left to biotechs and even CDMOs to develop therapies for neurodegenerative diseases?
JOE DE SOUSA | Director Science & Technology, Global Product Development | AstraZeneca
With genomics, proteomics, metabolomics and even microbiomics driving our search for new drugs, which -omics are coming next?
JASON LACOMBE | Chief Executive Officer | Veratrak
Interested in sponsorship opportunities? Need more information? Want to book group tickets?